^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor) +
    Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

    Excerpt:
    ...- Tumor must harbor an EGFR activating mutation (Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q)....
    Trial ID:
    NCT04545710
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Invest New Drugs
    Title:

    Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations

    Published date:
    02/15/2023
    Excerpt:
    In EGFR mutated cell lines, the combination of osimertinib and abemaciclib demonstrated synergistic effects, which were thought to be mediated by the inhibition of AKT phosphorylation.
    DOI:
    https://doi.org/10.1007/s10637-023-01337-8